Advertisement
UK markets closed

  • FTSE 100

    8,044.81
    +20.94 (+0.26%)
     

  • FTSE 250

    19,799.72
    +200.33 (+1.02%)
     

  • AIM

    755.74
    +6.56 (+0.88%)
     

  • GBP/EUR

    1.1619
    +0.0030 (+0.26%)
     

  • GBP/USD

    1.2430
    +0.0080 (+0.65%)
     

  • Bitcoin GBP

    53,491.49
    +442.31 (+0.83%)
     

  • CMC Crypto 200

    1,433.91
    +19.15 (+1.35%)
     

  • S&P 500

    5,062.26
    +51.66 (+1.03%)
     

  • DOW

    38,436.49
    +196.51 (+0.51%)
     

  • CRUDE OIL

    82.64
    +0.74 (+0.90%)
     

  • GOLD FUTURES

    2,333.60
    -12.80 (-0.55%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,137.65
    +276.85 (+1.55%)
     

  • CAC 40

    8,105.78
    +65.42 (+0.81%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

PCI Biotech Holding ASA publishes the Annual Report 2021

PCI Biotech Holding ASA
·2-min read
PCI Biotech Holding ASA
PCI Biotech Holding ASA

Oslo, Norway, April 28, 2022

The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2021 and the report is attached, in addition to the report according to the European Single Electronic Format (ESEF). The Annual Report 2021 is also available on the company’s website www.pcibiotech.com.

For further information, please contact:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 940 05 757

About PCI Biotech
PCI Biotech is a biopharmaceutical clinical stage development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities.

ADVERTISEMENT

The company’s lead programme fimaVacc aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. Enhancement of relevant immune responses with protein- and peptide-based vaccines were successfully demonstrated in humans through an extensive Phase I study in healthy volunteers and a Phase II study is in planning with the aim to demonstrate enhancement of immunotherapy for treatment of solid tumours. In the fimaNAc programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments